Generate Biomedicines (GENB) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.21 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | MLYS |
|---|---|---|
| Share price | $9.54 | $13.66 |
| Market cap | $1.23B | $1.21B |
| 1-day change | -8.00% | -3.53% |
| YTD return | — | -62.36% |
| 1-year return | — | -67.38% |
| EPS (TTM) | $-2.49 | $-4.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-154.65M |
| 52-week high | $22.67 | $44.13 |
| 52-week low | $9.40 | $13.57 |
| Distance from 52-week high | -57.92% | -69.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +183.02% | +218.89% |
| Average volume | 1.24M | 1.55M |
| Shares outstanding | 129.10M | 88.56M |
| Employees | 312 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
GENB vs MLYS FAQ
Which is bigger, Generate Biomedicines or Mineralys Therapeutics?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.21B for Mineralys Therapeutics (MLYS).
Are Generate Biomedicines and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.